-
1.发明授权
公开(公告)号：KR100960684B1
公开(公告)日：2010-05-31
申请号：KR1020080016505
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: C07K14/705 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A61K48/00 , C12N15/8509
Abstract: 본 발명은 TREM-2(Triggering Receptor Expressed on Myeloid cells-2) 유전자 또는 단백질을 포함하는 GA733-2 항원의 발현 억제 또는 검출용 조성물 및 방법, 및 이를 포함하는 형질전환 동물, 특히 형질전환 마우스 및 이의 사용방법에 관한 것으로서, 암, 특히 대장암의 원인 규명은 물론 그의 진단, 특히 조기진단 및 치료제 개발에 크게 기여할 수 있다.
TREM-2, GA733-2, 암, 대장암, 형질전환, 동물 모델, 마우스-
公开(公告)号：KR1020070030155A
公开(公告)日：2007-03-15
申请号：KR1020060109706
申请日：2006-11-07
Applicant: 전남대학교산학협력단 , 주식회사 굿셀라이프
IPC: C12N5/0783 , A61K35/17 , C12N9/12
CPC classification number: C12N5/0646 , A61K35/17 , C12N9/12
Abstract: A composition for differentiation of a mature natural killer(NK) cell and a method for production of the same mature natural killer cell are provided to produce a large quantity of mature natural killer cell to increase cancer-killing effects of the mature natural killer cell. The composition for differentiation of the mature natural killer cell from a precursor natural killer cell(pNK) comprises a ligand of Axl receptor tyrosine kinase. The method for producing the mature natural killer cell comprises the steps of: treating a hematopoietic stem cell with IL-7(interleukine 7), SCF(stem cell factor) and Flt3L(fms-related tyrosine kinase 3 ligand) to differentiate the hematopoietic stem cell into a precursor natural killer cell; and treating the precursor natural killer cell with the ligand of Axl receptor tyrosine kinase, wherein the mature killer cell is useful for treatment of cancers including large intestine cancer, breast cancer, non-Hodgikin's lymphoma and acute ymphocytic leukemia.
Abstract translation: 提供用于分化成熟天然杀伤（NK）细胞的组合物和用于生产相同成熟天然杀伤细胞的方法以产生大量的成熟天然杀伤细胞以增加成熟天然杀伤细胞的杀死癌症效果。 成熟天然杀伤细胞从前体天然杀伤细胞（pNK）分化的组合物包含Ax1受体酪氨酸激酶的配体。 用于生产成熟天然杀伤细胞的方法包括以下步骤：用IL-7（白细胞介素7），SCF（干细胞因子）和Flt3L（fms相关的酪氨酸激酶3配体）处理造血干细胞以分化造血干细胞 细胞成为前体天然杀伤细胞; 并用Ax1受体酪氨酸激酶的配体处理前体天然杀伤细胞，其中成熟的杀伤细胞可用于治疗包括大肠癌，乳腺癌，非霍奇金淋巴瘤和急性淋巴细胞性白血病的癌症。
-
公开(公告)号：KR1020070030114A
公开(公告)日：2007-03-15
申请号：KR1020060067483
申请日：2006-07-19
Applicant: 전남대학교산학협력단
Abstract: A method for production of natural killer(NK) cells is provided to treat cancers without side effects using the natural killer cells by using an Axl gene capable of promoting differentiation from hematopoietic stem cells into natural killer cells. The adult natural killer cells are produced by treating hematopoietic stem cells with IL-7(interleukine 7), SCF(stem cell factor) and Flt3L(fms-related tyrosine kinase 3 ligand), so as to differentiate them into NK precursor cells, and treating the NK precursor cells with the Axl gene, wherein the hematopoietic stem cells are isolated from human cord blood. A recombinant vector pLXSN-Axl contains the Axl gene. A transformant is produced by transforming a host cell, mouse RAW264.7 macrophage, with the recombinant vector pLXSN-Axl.
Abstract translation: 提供了一种生产天然杀伤（NK）细胞的方法，通过使用能促进从造血干细胞分化成自然杀伤细胞的Axl基因，使用天然杀伤细胞治疗无副作用的癌症。 通过用IL-7（白介素7），SCF（干细胞因子）和Flt3L（fms相关的酪氨酸激酶3配体）处理造血干细胞来产生成年自然杀伤细胞，以将它们分化成NK前体细胞，以及 用Axl基因处理NK前体细胞，其中从人脐血分离造血干细胞。 重组载体pLXSN-Ax1含有Axl基因。 通过用重组载体pLXSN-Ax1转化宿主细胞小鼠RAW264.7巨噬细胞来产生转化体。
-
公开(公告)号：KR1020070030115A
公开(公告)日：2007-03-15
申请号：KR1020060067485
申请日：2006-07-19
Applicant: 전남대학교산학협력단
Abstract: A method for production of a natural killer(NK) cell is provided to avoid side effects in cancer therapy by using a natural killer cell differentiated from a hematopoietic stem cell instead of a matured natural killer cell. The adult natural killer cell is produced by treating the hematopoietic stem cell with IL-7(interleukine 7), SCF(stem cell factor) and Flt3L(fms-related tyrosine kinase 3 ligand) to differentiate the hematopoietic stem cell into a NK precursor cell, and treating the NK precursor cell with the Axl receptor and its ligand Gas6. The hematopoietic stem cell is isolated from the human cord blood; the Axl is a recombinant Axl produced from a transformant containing a recombinant vector pLXSN-Axl; the host cell of the transformant containing the recombinant vector pLXSN-Axl is a mouse RAW264.7 macrophage; the recombinant Gas6 is produced from a transformant containing a recombinant vector pcDNA3.1(+)-GAS6; and the host cell of the transformant containing the recombinant vector pcDNA3.1(+)-GAS6 is a mouse OP9 cell line.
Abstract translation: 提供了一种生产自然杀伤（NK）细胞的方法，以通过使用从造血干细胞分化而不是成熟的天然杀伤细胞分化的天然杀伤细胞来避免癌症治疗中的副作用。 通过用IL-7（白细胞介素7），SCF（干细胞因子）和Flt3L（fms相关的酪氨酸激酶3配体）处理造血干细胞以将造血干细胞分化成NK前体细胞来产生成年自然杀伤细胞 ，并用Ax1受体及其配体Gas6处理NK前体细胞。 造血干细胞从人脐带血中分离出来; Ax1是由含有重组载体pLXSN-Ax1的转化体产生的重组Ax1; 含有重组载体pLXSN-Ax1的转化体的宿主细胞是小鼠RAW264.7巨噬细胞; 重组Gas6由含有重组载体pcDNA3.1（+）-GAS6的转化体产生; 含有重组载体pcDNA3.1（+） - GAS6的转化体的宿主细胞是小鼠OP9细胞系。
-
公开(公告)号：KR100967623B1
公开(公告)日：2010-07-05
申请号：KR1020080016523
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00 , A61P35/00
Abstract: 본 발명은 유효성분으로서 림포톡신 α/β 복합체(Lymphotoxin α/β Complex, LTα/β) 또는 림포톡신 β 수용체(Lymphotoxin β receptor, LTβ-R) 결합제를 포함하는, 자궁경부암 예방 또는 치료용 조성물에 관한 것으로서, 점막면역 반응을 효과적으로 유도함으로써 자궁경부암의 예방 또는 치료제로 유용하게 이용될 수 있다.
림포톡신, 림포톡신 α/β 복합체, LTα/β, 림포톡신 β 수용체, LTβ-R, 점막면역, 인유두종바이러스, HPV, E6, 자궁경부암-
Patent Agency Ranking
公开(公告)号：KR1020090090952A
公开(公告)日：2009-08-26
申请号：KR1020080016531
申请日：2008-02-22
Applicant: 전남대학교산학협력단
IPC: A61K39/395 , A61K38/00
CPC classification number: A61K38/44 , A61K38/005 , A61K38/1774 , A61K39/395 , C12N15/62 , Y10S514/886
Abstract: A composition for regulating or detecting gamma-delta T cell or cytokines secreted by the gamma-delta T cell, which contains Axl receptor tyrosine kinase, its ligand or inhibitor is provided to regulate gamma-delta T cell and prevent or treat inflammatory bowl diseases (IBD). A composition for regulating gamma-delta T cell or a cytokine which is secreted by the gamma-delta T cell comprises an Axl receptor tyrosine kinase, its ligand or its inhibitor as an active ingredient. The composition is used for preventing and treating inflammatory bowel disease. A method for screening an agent for preventing and treating inflammatory bowel disease comprises: a step of adding a test compound in Axl receptor tyrosine kinase, its ligand or inhibitor; and a step of researching the influence of test compound on the expression or activation of Axl receptor tyrosine kinase, gamma-delta T cell, or cytokine secreted by the gamma-delta T cell.
Abstract translation: 提供用于调节或检测由含有Ax1受体酪氨酸激酶，其配体或抑制剂的γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物，以调节γ-δT细胞并预防或治疗炎性碗疾病（ IBD）。 用于调节由γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物包含Ax1受体酪氨酸激酶，其配体或其抑制剂作为活性成分。 该组合物用于预防和治疗炎症性肠病。 用于筛选用于预防和治疗炎症性肠病的药剂的方法包括：在Ax1受体酪氨酸激酶，其配体或抑制剂中加入测试化合物的步骤; 以及研究化合物对由γ-δT细胞分泌的Axl受体酪氨酸激酶，γ-δT细胞或细胞因子的表达或活化的影响的步骤。
-
公开(公告)号：KR1020090090944A
公开(公告)日：2009-08-26
申请号：KR1020080016520
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: A61K48/00 , A61K2039/585 , C12N9/12
Abstract: A method for screening therapeutic agent or suppressing tumor by regulating Axl signal is provided to increase the sensitivity of natural killer cell by the expression of LIGHT gene and induce apoptosis of tumor cell. A composition for suppressing tumor comprises LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry mediator on T cells) (TNFSF14) or its activator as an active ingredient. The activator is Axl receptor tyrosine kinase or its ligand. The Axl ligand is an antibody to Axl antibody, gamma-carboxylated Gas-6(growth-arrest specific gene 6) or protein S. The tumor is lymphatic tumor. A method for screening agent for suppressing or treating tumor comprises: a step of adding a test compound to a LIGHT (TNFSF14) or its activator; and a step of researching the influence of the test compound on the expression or activation of LIGHT or its activator.
Abstract translation: 提供通过调节Axl信号筛选治疗剂或抑制肿瘤的方法，以通过LIGHT基因的表达增加自然杀伤细胞的敏感性并诱导肿瘤细胞凋亡。 用于抑制肿瘤的组合物包括LIGHT（与蛋白D竞争结合于T细胞上的疱疹病毒进入介导蛋白的竞争性淋巴毒素样诱导蛋白）（TNFSF14）或其活化剂作为活性成分。 活化剂是Axl受体酪氨酸激酶或其配体。 Axl配体是Ax1抗体，γ-羧化气体-6（生长停滞特异性基因6）或蛋白S的抗体。肿瘤是淋巴瘤。 用于抑制或治疗肿瘤的筛选剂的方法包括：将测试化合物加入到LIGHT（TNFSF14）或其活化剂中的步骤; 以及研究化合物对LIGHT或其活化剂表达或活化的影响的一个步骤。
-
8.发明公开
公开(公告)号：KR1020090090935A
公开(公告)日：2009-08-26
申请号：KR1020080016505
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: C07K14/705 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A61K48/00 , C12N15/8509
Abstract: A composition for detecting or suppressing the expression of GA733-2 antigen containing TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) gene or protein is provided to use in the investigation of cancer cause, early diagnosis of cancer and development of therapeutic agent. A composition for suppressing the expression of GA733-2 antigen comprises a TREM-2 (Triggering Receptor Expressed on Myeloid cells-2) gene or protein as an active ingredient. The expression of GA733-2 antigen in a biological sample is suppressed by adding TREM-2 gene or protein. A method for screening an agent for suppressing and treating cancer comprises: a step of adding a TREM-2 gene or protein or candidate drug which suppresses or treat cancer into transgenic animal which is transformed with TREM-2 gene; and a step of researching the influence of the candidate drug on the expression or activation of TREM-2 or GA733-2. The cancer is colon cancer.
Abstract translation: 提供了用于检测或抑制含有TREM-2（触发受体表达于骨髓细胞-2）基因或蛋白质的GA733-2抗原表达的组合物用于癌症原因的调查，癌症的早期诊断和治疗剂的发展 。 用于抑制GA733-2抗原表达的组合物包含TREM-2（以骨髓细胞-2表达的触发受体）基因或蛋白质作为活性成分。 通过添加TREM-2基因或蛋白质抑制生物样品中GA733-2抗原的表达。 用于筛选抑制和治疗癌症的药剂的方法包括：向TREM-2基因转化的转基因动物中加入抑制或治疗癌症的TREM-2基因或蛋白质或候选药物的步骤; 研究候选药物对TREM-2或GA733-2表达或激活的影响的一个步骤。 癌症是结肠癌。
-
公开(公告)号：KR1020090090918A
公开(公告)日：2009-08-26
申请号：KR1020080016480
申请日：2008-02-22
Applicant: 전남대학교산학협력단
CPC classification number: A61K38/005 , A61K48/00
Abstract: A composition for preventing and treating cervical cancer, which contains AxL receptor tyrosine kinase inhibitor is provided to regulate the expression of human papilloma virus (HPV) type 16 E6 gene and reduce the proliferation and metastatic property of cancer cell. A composition for preventing and treating cervical cancer comprises an inhibitor of Axl receptor tyrosine kinase as an active ingredient. A method for screening an agent for preventing and treating cervical cancer comprises: a step of adding a test compound to the Axl receptor tyrosine kinase; and a step of researching the influence of the test sample to the expression or activation of Axl and selecting a compound which suppresses the expression or activation of Axl.
Abstract translation: 提供含有AxL受体酪氨酸激酶抑制剂的宫颈癌预防和治疗组合物，用于调节人乳头状瘤病毒（HPV）16型E6基因的表达，降低癌细胞的增殖和转移性。 用于预防和治疗宫颈癌的组合物包含Ax1受体酪氨酸激酶的抑制剂作为活性成分。 用于筛选预防和治疗宫颈癌的药剂的方法包括：将测试化合物加入到Ax1受体酪氨酸激酶中的步骤; 研究测试样品对Axl的表达或活化的影响并选择抑制Ax1表达或激活的化合物的步骤。
-
公开(公告)号：KR1020080008060A
公开(公告)日：2008-01-23
申请号：KR1020060067484
申请日：2006-07-19
Applicant: 전남대학교산학협력단
Abstract: A method for preparing a natural killer cell is provided to treat cancer by obtaining the adult natural killer cell from an adult stem cell. A method for preparing a natural killer cell comprises the steps of: (a) treating an adult stem cell derived from cord blood of human with IL-7, SCF and Flt3L to be differentiated into a natural killer precursor cell; and (b) treating the natural killer precursor cell with Gas6. A transfectant comprises a recombinant vector pcDNA3.1(+)-GAS6.
Abstract translation: 提供一种制备自然杀伤细胞的方法，通过从成体干细胞获得成年自然杀伤细胞来治疗癌症。 制备天然杀伤细胞的方法包括以下步骤：（a）用IL-7，SCF和Flt3L处理源自人脐血的成体干细胞以分化为天然杀伤细胞前体细胞; 和（b）用Gas6处理天然杀伤前体细胞。 转染子包含重组载体pcDNA3.1（+）-GAS6。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.023 seconds)
